Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects

NCT04440345 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Overweight or Obesity

Interventions

DRUG: IBI362
DRUG: Placebo

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.